Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Stem Cell Research

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options.
• Breast cancer stem cells (BCSCs) are implicated in tumor recurrence and metastasis.
• Targeting BCSCs offers a promising strategy for effective TNBC treatment.

Purpose of the Study:

• To evaluate the efficacy of five signaling pathway inhibitors as novel therapeutic agents against BCSCs in TNBC.
• To investigate the in vitro and in vivo effects of these inhibitors on TNBC cell proliferation, invasion, apoptosis, and self-renewal.
• To explore the potential of these inhibitors for clinical application in TNBC patients.

Main Methods:

• In vitro studies utilized MTT assays, Matrigel invasion assays, flow cytometry, and mammosphere assays on the HCC38 TNBC stem cell line.
• In vivo studies involved xenograft mouse models using the HCC1806 TNBC stem cell line.
• Assessment of protein expression and phosphorylation of downstream signaling molecules was performed.

Main Results:

• Signaling pathway inhibitors significantly reduced TNBC cell proliferation, invasion, and mammosphere formation in vitro.
• These agents induced apoptosis in TNBC cells by inhibiting key signaling molecules.
• In vivo studies demonstrated effective suppression of tumor formation and growth in xenograft models.

Conclusions:

• The investigated signaling pathway inhibitors demonstrate significant potential as novel therapeutic agents targeting BCSCs in TNBC.
• These findings suggest a promising therapeutic strategy for TNBC by targeting BCSCs.
• The study provides valuable insights for potential clinical applications in TNBC treatment.